ArticleOncology letters2026
SUMOylation inhibitor TAK-981 suppresses proliferation and induces apoptosis in SK-UT-1B uterine leiomyosarcoma cells.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine leiomyosarcoma (Ut-LMS) is an aggressive smooth muscle malignancy with limited therapeutic options and a poor prognosis, underscoring the need for new molecularly-targeted therapies. TAK-981 (subasumstat), a selective inhibitor of small ubiquitin-like modifier (SUMO)-activating enzymes, exhibits antitumor activity in several types of cancer; however, to the best of our knowledge, its therapeutic potential in Ut-LMS has not been explored. The current study evaluated the effects of TAK-981 on human Ut-LMS cells and revealed that SK-UT-1B cells exhibited markedly greater sensitivity to TAK-981 than SK-UT-1 cells. TAK-981 substantially reduced SK-UT-1B cell viability in a time- and concentration-dependent manner, whereas SK-UT-1 cells demonstrated a minimal response to TAK-981 at similar doses. Annexin V staining confirmed that TAK-981 induced the apoptosis of SK-UT-1B cells after 48 h, with apoptotic populations increasing proportionally with drug concentration. Furthermore, TAK-981 induced G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.